Slide 1: Investor Presentation Intimation Letter to Exchanges
108/LG/SE/MAY/2024/GBSL May 29, 2024 To, To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex, Dalal Street, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 509079 Scrip Symbol: GUFICBIO Subject: Investor Presentatio
Slide 2: Delivering Care & Cure - Investor Presentation May 2024
Delivering Care & Cure Investor Presentation May 2024
Slide 3: Safe Harbor
Safe Harbor This presentation has been prepared by and is the sole responsibility of Gufic Biosc iences Limited (the “ Company”). By accessing this presentation, you are agreeing to be bound by the trailing restrictions. This presentation does not constitute or form part of any offer or invitation o
Slide 4: H2 FY24 Business & Financial Highlights
H2 FY24 Business & Financial Highlights
Slide 5: H2 FY24 Business Highlights
H2 FY24 Business Highlights Indore Capex Update: Ongoing Manufacturing Facility Qualification and Trial Runs: We are conducting thorough media fill validation studies prior to commencing commercial production. Media fill validation, also known as aseptic process simulation, involves filling vials wi
Slide 6: H2 FY24 Business Highlights
H2 FY24 Business Highlights Critical Care Division Domestic Business Breakup Critical Care has achieved sustained growth through enhanced market penetration and continued leadership in Critical Care Division niche antibacterial and antifungal products. Our unique engagement initiatives with patients
Slide 7: H2 FY24 Business Highlights
H2 FY24 Business Highlights Differentiated launches: Merofic Dual Chamber Bag (Meropenem DCB): A first-of-its-kind innovation in India. This closed drug delivery system ensures zero human intervention, setting a new standard in medication safety and efficacy. The Merofic Dual Chamber Bag sets Gufic
Slide 8: H2 FY24 Business Highlights
H2 FY24 Business Highlights In-licensed a novel pain management solution, first time in India Type of Molecule: Synthetic Analgesic with mechanism of action similar to an opioid without any of its side effects Therapeutic Category: Pain Management Mechanism of Action: a unique mechanism of action. I
Slide 9: H2 FY24 Business Highlights
H2 FY24 Business Highlights Ferticare Division All round growth: There was a healthy growth in this division, driven by better doctor coverage, improved product offering and field efficiency Pipeline: Strengthened the assisted reproductive technologies (ART) portfolio by launching differentiated pro
Slide 10: H2 FY24 Business Highlights
H2 FY24 Business Highlights Sprak, Stellar & Healthcare Division: Spark, Stellar & Healthcare division has continued to grow due to our comprehensive strategy, which includes knowledge-sharing programs, portfolio diversification, and enhanced field force efficiency. Some of the key initiatives drivi
Slide 11: H2 FY24 Business Highlights
H2 FY24 Business Highlights Sparsh Division Uniqueness and Market Approach: The Sparsh Division stands out for its direct-to-hospital distribution model. This innovative approach provides better visibility of sales and offers hospitals more competitive pricing. Strong Market Penetration: Extensive H
Slide 12: H2 FY24 Business Highlights
H2 FY24 Business Highlights Aestherderm Division: The division is steadily growing, driven by knowledge sharing and unique training programs such as Aesthaderm's GROW Program: Advancing aesthetic dermatology by training doctors in the effective use of botulinum toxin. Benefits of the GROW Program: T
Slide 13: H2 FY24 Business Highlights
H2 FY24 Business Highlights Neuro Care Division: Zarbot Market Acceptance: Gufic's Neuro Care Division is spreading awareness and creating a market for Zarbot, the 1st Indian Botulinum Toxin A of international pedigree. Zarbot gains the confidence of leading neurologists within one year of launch, w
Slide 14: Research & Development
Research & Development Update on R&D Update on Selvax • Peptides R&D: Paving the Way for In-house Critical • Positive Results from Mouse Studies: API Manufacturing: Our foray into peptides research and development aligns seamlessly with our broader • Selvax conducted comprehensive studies in mice us
Slide 15: Strategic Initiatives
Strategic Initiatives Strategic Initiatives that will further amplify growth over the next few years Increase in overall market and market share in Leverage new biological Botulinum Toxin range of Increase market share in technology platform to products through Commercialization of contract manufact
Slide 16: Profit & Loss Statement
Profit & Loss Statement Pa r t i c u l a rs ( i n R s . C r o re) Q4 FY24 Q4 FY23 FY24 FY23 To ta l Rev e n u e 194.9 173.0 806.7 690.6 E B I T DA 34.6 32.8 148.05 137.2 E B I T DA M a r g i n % 17.8% 18.9% 18.4% 19.9% P ro f i t b efo re Ta x 26.6 23.9 115.7 106.7 P BT M a r g i n s % 13.6% 13.8% 1
Slide 17: Company Overview
Company Overview
Slide 18: About Gufic Biosciences
About Gufic Biosciences Research based Pharmaceutical Company recognized for its innovative, high quality Pharmaceuticals Nutraceuticals, Natural Herbal products One of the Largest Manufacturers of Lyophilized Injections in India with a wide range of products in various therapy areas BUSINESS STRUCT
Slide 19: World Class Manufacturing Infrastructure
World Class Manufacturing Infrastructure Unit - I at Navsari Unit - II at Navsari Gufic - Belgaum Botulinum Toxin Facility Lyophilized Injectables Facility Natural Products Facility Lyophilized/Powder Injectables Facility Capability to manufacture Liposomal Amphotericin B and Depot Injections Natura
Slide 20: Upcoming World Class Manufacturing Infrastructure
Upcoming World Class Manufacturing Infrastructure Unit - III at Indore Penem Block UPDATE ON CAPEX Indore Lyophilized/Powder Injectables Dedicated facility for Penem Received Drug Manufacturing License from FDA, Madhya Facility Carbapenems (Lyophilized / Dry Pradesh Capability to cater to regulated
Slide 21: Botulinum Toxin Facility
Botulinum Toxin Facility Gufic has built a state-of-the-art manufacturing facility for Botulinum Toxin in Navsari Gufic has partnered with Prime Bio, USA for manufacturing Botulinum Toxin API and formulation Gufic is equipped with all the necessary analytical testing procedures for safety and effica
Slide 22: Consolidating the Domestic Branded Business
Consolidating the Domestic Branded Business Products CRITICAL CARE INFERTILITY MASS SPECIALITY 100+ SKU’s Field Force: 250 Field Force: >150 Field Force: >180 200+ Therapy Areas: Antibacterial, Therapy Areas: Hormones, Therapy Areas: Anti Infectives, Antifungal, Pain Management, Recombinant Products
Slide 23: Expanding Creditability in CMO Business
Expanding Creditability in CMO Business Offer CMO services for India and 70+ 150+ Products Reliable CMO service for quality products over a Global Markets Companies across multiple therapy areas decade One of the Largest Supplier of Formulations Liposomal Doxycycline Tigecycline Gonadotropins Micafu
Slide 24: Expanding Geographical Reach
Expanding Geographical Reach 130+ Products registered globally (in 15+ countries) 150+ Products in pipeline for registration (in 30+ countries) CANADA | COSTA RICA | PANAMA | COLUMBIA | CHILE | LATVIA | LITHUANIA | BELARUS | GERMANY | AUSTRIA | PORTUGAL | MOROCCO ALGERIA | DOMINICAN REPUBLIC | VENEZ
Slide 25: Building API Capabilities
Building API Capabilities Special Facility dedicated to API Focused on developing non The categories of API’s infringing, novel, cost manufactured are effective and scalable antifungals, antibacterial, chemical process for APIs, anesthetics and Peptides and Cyclopeptides intermediates for antifungal
Slide 26: Strong Partnership & Licensing Deals
Strong Partnership & Licensing Deals Through our collaborations with global partners that are European leader in IV drug researching to expand the frontiers of pharma and delivery systems. Collaborated biotechnology, Gufic will be a technology bridge to the with Gufic to launch Dual future of health
Slide 27: Extensive Sales, Distribution & IT Infrastructure in India
Extensive Sales, Distribution IT Infrastructure in India 2 Central Warehouses Pan India Presence with a located in North Delhi and field force of 1,000+ West Bhiwandi IT Infrastructure Retail coverage of more than 23 Carrying & Forwarding (C&F) agents across India Integrated IT Systems with Sales 1,
Slide 28: Growth Levers
Growth Levers 1 2 3 INTERNATIONAL INDIA BUSINESS CMO BUSINESS BUSINESS • Consolidation of the Critical Care Infertility • Expand our presence in regulated • Scale up the manufacturing capacity business markets such as US EU • Entry into new therapy areas Dermatology - • Consolidation of the clients
Slide 29: Our Robust R&D and Clinical team to augment growth
Our Robust R&D and Clinical team to augment growth Research & Development (R&D) Clinical Team State-of-the-art R&D Facility in Navsari, Gujarat with expertise in Formulation Development Technology Transfer API Development Patents in various therapy areas Granted: 5 Filed/In-process of filling : 8 Ma
Slide 30: Historical Financials
Historical Financials
Slide 31: Historical Financials
Historical Financials Particulars (Rs. Crs.) FY24 FY23 FY22 FY21 FY20 FY19 Total Revenue 808.8 693.2 782.3 491.4 384.6 359.5 EBITDA 148.0 137.2 151.1 87.7 57.9 56.7 EBITDA Margin % 18.3% 19.8% 19.3% 17.8% 15.1% 15.8% Profit before Tax 115.7 106.7 126.8 57.7 30.1 40.2 PBT Margin % 14.3% 15.4% 16.2% 1
Slide 32: Historical Balance Sheet (Equity & Liabilities)
Historical Balance Sheet (Equity & Liabilities) EQUITY & LIABILITIES (Rs. Crs.) Mar-24 Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Equity Share Capital 10 9.7 9.7 9.7 9.7 7.8 Other Equity 522.5 338.1 259.4 163.7 119.6 67.6 Total Equity 532.5 347.8 269.1 173.4 129.3 75.3 Non-Current Liabilities Financial Liab
Slide 33: Historical Balance Sheet (Assets)
Historical Balance Sheet (Assets) ASSETS (Rs. Crs.) Mar-24 Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Non-Current Assets Property, plant and equipment 138.3 126.8 105.5 93.8 72.7 70.3 Intangible assets 5.6 0.7 0.6 0.4 0.6 0.4 Capital work-in-progress 307.1 169.6 40.9 13.4 30.6 9.6 Right of use assets 14.9 3
Slide 34: Historical Cash Flows
Historical Cash Flows Cash Flow Statement (Rs. Crs.) FY24 FY23 FY22 FY21 FY20 FY19 Net Profit Before Tax 115.7 106.7 126.9 57.7 30.1 35.3 Adjustments for: Non - Cash Items / Other Investment or 34.1 29.6 23.2 30.8 24.7 13.4 Financial Items Operating profit before working capital changes 149.8 136.4
Slide 35: Thank You
THANK YOU Company: Gufic Biosciences Limited CIN: L24100MH1984PLC033519 Mr. Avik Das – Investor Relations avik.das@guficbio.com Tel: +91 22 67261000